ArticleMetabolomics : Official journal of the Metabolomic Society2018
Metabolic signatures of four major histological types of lung cancer cells.
Article in Metabolomics : Official journal of the Metabolomic Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Integrating multi-omics approaches reveals metabolic reprogramming and identifies PDHX as a candidate node in triptolide-treated non-small Cell lung cancer.Frontiers in pharmacology · 2026Article
- Plasma metabolites as biomarkers for screening and differential diagnosis of lung cancer.Journal of cardiothoracic surgery · 2025Article
- Characterizing Plasma-Based Metabolomic Signatures for Metastasis in Non-Small Cell Lung Cancer.Metabolites · 2025Article
- Transfer Learning in Cancer Genetics, Mutation Detection, Gene Expression Analysis, and Syndrome Recognition.Cancers · 2024Review
- Effect of Short-Chain Fatty Acids and Polyunsaturated Fatty Acids on Metabolites in H460 Lung Cancer Cells.Molecules (Basel, Switzerland) · 2023Article
- LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer.Molecular cancer · 2022Article
- Identification of pyroptosis-related long non-coding RNAs with prognosis and therapy in lung squamous cell carcinoma.Scientific reports · 2022Article
- Plasm Metabolomics Study in Pulmonary Metastatic Carcinoma.Journal of oncology · 2022Article
- Profiling of amines in biological samples using polythioester-functionalized magnetic nanoprobe.Frontiers in bioengineering and biotechnology · 2022Article
- Identifying metabolic alterations in newly diagnosed small cell lung cancer patients.Metabolism open · 2021Article
- Evaluation of Anti-Inflammatory Effects of Celery Leaf and Stem Extracts in LPS-Induced RAW 264.7 Cells Using Nitric Oxide Assay and LC-MS Based Metabolomics.Current issues in molecular biology · 2021Article
- Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma.Oncology letters · 2021Article
- Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer.Frontiers in oncology · 2021Article
- Construction of a prognostic model for lung adenocarcinoma based on bioinformatics analysis of metabolic genes.Translational cancer research · 2020Article
- Methylation‑driven genes PMPCAP1, SOWAHC and ZNF454 as potential prognostic biomarkers in lung squamous cell carcinoma.Molecular medicine reports · 2020Article
- [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019Article
- Mechanism of Action for HDAC Inhibitors-Insights from Omics Approaches.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionHistologically lung cancer is classified into four major types: adenocarcinoma (Ad), squamous cell carcinoma (SqCC), large cell carcinoma (LCC), and small cell lung cancer (SCLC). Presently, our understanding of cellular metabolism among them is still not clear.
objectivesThe goal of this study was to assess the cellular metabolic profiles across these four types of lung cancer using an untargeted metabolomics approach.
methodsSix lung cancer cell lines, viz., Ad (A549 and HCC827), SqCC (NCl-H226 and NCl-H520), LCC (NCl-H460), and SCLC (NCl-H526), were analyzed using liquid chromatography quadrupole time-of-flight mass spectrometry, with normal human small airway epithelial cells (SAEC) as the control group. The principal component analysis (PCA) was performed to identify the metabolic signatures that had characteristic alterations in each histological type. Further, a metabolite set enrichment analysis was performed for pathway analysis.
resultsCompared to the SAEC, 31, 27, 34, 34, 32, and 39 differential metabolites mainly in relation to nucleotides, amino acid, and fatty acid metabolism were identified in A549, HCC827, NCl-H226, NCl-H520, NCl-H460, and NCl-H526 cells, respectively. The metabolic signatures allowed the six cancerous cell lines to be clearly separated in a PCA score plot.
conclusionThe metabolic signatures are unique to each histological type, and appeared to be related to their cell-of-origin and mutation status. The changes are useful for assessing the metabolic characteristics of lung cancer, and offer potential for the establishment of novel diagnostic tools for different origin and oncogenic mutation of lung cancer.
Indexed as
Identifiers
30830374What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.